Response to measles-mumps-rubella vaccine in children with autism spectrum disorders

In Vivo

Volumn 27, Issue 3, 2013, Pages 377-382

  Gentile, Ivan ^a   Bravaccio, Carmela ^a   Bonavolta, Raffaele ^a   Zappulo, Emanuela ^a   Scarica, Sabrina ^a   Riccio, Maria Pia ^b   Settimi, Alessandro ^a   Portella, Giuseppe ^a   Pascotto, Antonio ^b   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Autism spectrum disorders; Autistic disorder; MMR vaccine; Seropositivity

Indexed keywords

ANTIBODY; MEASLES MUMPS RUBELLA VACCINE;

ANTIBODY TITER; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEASLES; MUMPS; PRESCHOOL CHILD; RUBELLA; SEROLOGY; VACCINATION;

EID: 84876912053     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Libbey JE, Coon HH, Kirkman NJ, Sweeten TL, Miller JN, Lainhart JE, McMahon WM and Fujinami RS: Are there altered antibody responses to measles, mumps, or rubella viruses in autism? J Neurovirol 13: 252-259, 2007.
2. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E and Rutter M: Autism as a strongly genetic disorder: Evidence from a British twin study. Psychol Med 25: 63-77, 1995.
3. Coleman M and Gillberg C: The Biology of the Autistic Syndromes. New York, Praeger Publishers, 1985.
4. Engel SM and Daniels JL: On the complex relationship between genes and environment in the etiology of autism. Epidemiology. 22: 486-488, 2011.
5. Gillberg C and Wing L: Autism: not an extremely rare disorder. Acta Psychiatr Scand 99: 399-406, 1999.
6. Chakrabarti S and Fombonne E: Pervasive developmental disorders in preschool children. JAMA 285: 3093-3099, 2001.
7. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C and Murphy C: Prevalence of autism in a US metropolitan area. JAMA 289: 49-55, 2003.
8. King CR: A novel embryological theory of autism causation involving endogenous biochemicals capable of initiating cellular gene transcription: A possible link between twelve autism risk factors and the autism 'epidemic'. Med Hypotheses 76: 653-660, 2011.
9. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ. 61: 1-19, 2012.
10. Fombonne E and Chakrabarti S: No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 108: E58, 2001.
11. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE and Walker-Smith JA: Ileal-lymphoidnodular hyperplasia, nonspecific colitis, and pervasive developmental disorder in children. Lancet 351: 637-641, 1998 (retracted).
12. Singh VK, Lin SX and Yang VC: Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin Immunol Immunopathol 89: 105-108, 1998.
13. Baird G, Pickles A, Simonoff E, Charman T, Sullivan P, Chandler S, Loucas T, Meldrum D, Afzal M, Thomas B, Jin L and Brown D: Measles vaccination and antibody response in autism spectrum disorders. Arch Dis Child 93: 832-837, 2008.
14. Singh VK, Lin SX, Newell E and Nelson C: Abnormal measlesmumps-rubella antibodies and CNS autoimmunity in children with autism. J Biomed Sci 9: 359-364, 2002.
15. Singh VK and Jensen RL: Elevated levels of measles antibodies in children with autism. Pediatr Neurol 28: 292-294, 2003.
16. Kawashti MI, Amin OR and Rowehy NG: Possible immunological disorders in autism: concomitant autoimmunity and immune tolerance. Egypt J Immunol 13: 99-104, 2006.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 2000.
18. Lord C, Rutter M and Le Couteur A: Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24: 659-685, 1994.
19. Schopler E, Reichler RJ and Renner BR: The Childhood Autism Rating Scale (CARS). Los Angeles, Western Psychological Service Inc., 1988.
20. Lord C, Risi S, Lambrecht L, Cook EH Jr., Leventhal BL, DiLavore PC, Pickles A and Rutter M: The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30: 205-223, 2000.
21. Sparrow SS, Balla DA and Cicchetti DV: Vineland Adaptive Behavior Scales. Intervista, forma completa. Balboni G and Pedrabissi L (eds.). Firenze, Italy: Giunti O.S., 1984.
22. Griffiths R: GDMS-Griffiths Mental Development Scales. Firenze, Italy: Giunti O.S., 2006.
23. Tookey P: Rubella in England, Scotland and Wales. Euro Surveill 9: 21-23, 2004.
24. Jansen VAA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ and Rhodes CJ: Measles outbreaks in a population with declining vaccine uptake. Science 301: 804, 2003.
25. Flaherty DK: The vaccine- autism connection: A public health crisis caused by unethical medical practices and fraudulent science. Ann Pharmacother 45: 1302-1304, 2011.
26. DeStefano F: MMR vaccine and autism: A review of the evidence for a causal association. Mol Psychiatry 7(Suppl 2): S51-S52, 2002.
27. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL and Phillips TM: Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 49: 597-606, 2001.
28. Panitch HS, Hooper CJ and Johnson KP: CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol 37: 206-209, 1980.
29. Bernard CC, Townsend E, Randell VB and Williamson HG: Do antibodies to myelin basic protein isolated from multiple sclerosis cross-react with measles and other common virus antigens? Clin Exp Immunol 52: 98-106, 1983.
30. Rubio N and Cuesta A: Lack of cross-reaction between myelin basic proteins and putative demyelinating virus envelope proteins. Mol Immunol 26: 663-668, 1989.
31. Jingwu Z, Chin Y, Henderikx P, Medaer R, Chou C-HJ and Raus JC: Antibodies to myelin basic protein and measles virus in multiple sclerosis: Precursor frequency analysis of the antibodyproducing B-cells. Autoimmunity 11: 27-34, 1991.
32. Libbey JE, Coon HH, Kirkman NJ, Sweeten TL, Miller JN, Stevenson EK, Lainhart JE, McMahon WM and Fujinami RS: Are there enhanced MBP autoantibodies in autism? J Autism Dev Disord 38: 324-32, 2008.
33. Afzal MA, Pipkin PA and Minor PD: Absence of chicken myelin basic protein residues in commercial formulations of MMR vaccine. Vaccine 19: 442-446, 2000.
34. Asher DM: Slow viral infections of the human nervous system. In: Infections of the Central Nervous System. Scheld WM, Whitley RJ and Durack DT (eds.). New York: Raven Press, pp. 145-166, 1991.
35. Garg RK: Subacute sclerosing panencephalitis. Postgrad Med J 78: 63-70, 2002.
36. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J and Waight PA: Autism and measles, mumps, and rubella vaccine: No epidemiological evidence for a causal association. Lancet 353: 2026-2029, 1999.
37. Taylor B, Miller E, Lingam R, Andrews N, Simmons A and Stowe J: Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: Population study. BMJ 324: 393-396, 2002.
38. Smeeth L, Cook C, Fombonne E, Heavey L, Rodrigues LC, Smith PG and Hall AJ: MMR vaccination and pervasive developmental disorders: A case-control study. Lancet 364: 963-969, 2004.
39. Hensley E and Briars L: Closer look at autism and the measles-mumps-rubella vaccine. J Am Pharm Assoc 50: 736-741, 2010.
40. Makela A, Nuorti JP and Peltola H: Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 110: 957-963, 2002.
41. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J and Melbye M: A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 347: 1477-1482, 2002.
42. Dales L, Hammer SJ and Smith NJ: Time trends in autism and in MMR immunization coverage in California. JAMA 285: 1183-1185, 2001.
43. Kaye JA, del Mar Melero-Montes M and Jick H: Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: A time trend analysis. BMJ 322: 460-463, 2001.
44. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I and Paunio M: No evidence for measles, mumps, and rubella vaccineassociated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 351: 1327-1328, 1998.
45. Peterson MR and Torrey EF: Viruses and other infectious agents as behavioral teratogens. In: The Autistic Syndromes. Coleman M (ed.). New York: American Elsevier, pp. 23-42, 1976.
46. Mrozek-Budzyn D, Kiełtyka A and Majewska R: Lack of association between measles-mumps-rubella vaccination and autism in children: A case-control study. Pediatr Infect Dis J 29: 397-400, 2010.
47. Farrington CP, Miller E and Taylor B: MMR and autism: Further evidence against a causal association. Vaccine 19: 3632-3635, 2001.